Matthew Henn
Vermögen: 57 374 $ am 31.05.2026
Vermögen: 57 374 $ am 31.05.2026
Matthew R.
Henn is currently Director at The Microbiome Therapeutics Innovation Group and President & Chief Scientific Officer at Seres Therapeutics, Inc. Former roles include Director at Viral Genomics, Inc. and Director-Viral Genomics at The Broad Institute, Inc. from 2005 to 2012.
Education includes a doctorate from the University of California, Berkeley and an undergraduate degree from the University of New Hampshire.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 18.05.2026 | 7’838 ( 0.08% ) | 57 374 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| SERES THERAPEUTICS, INC. | Präsident | 02.03.2026 |
| Unternehmen | Position | Ende |
|---|---|---|
The Broad Institute, Inc.
The Broad Institute, Inc. BiotechnologyHealth Technology Engages in research and development in bio medicals to cure infectious disease, cancer, psychiatric research and cardiovascular diseases | Corporate Officer/Principal | 01.06.2012 |
Viral Genomics, Inc. | Direktor/Vorstandsmitglied | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
University of California, Berkeley
University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of New Hampshire
University of New Hampshire Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Viral Genomics, Inc. | |
The Broad Institute, Inc.
The Broad Institute, Inc. BiotechnologyHealth Technology Engages in research and development in bio medicals to cure infectious disease, cancer, psychiatric research and cardiovascular diseases | Health Technology |
Seres Therapeutics, Inc.
Seres Therapeutics, Inc. BiotechnologyHealth Technology Develops novel treatments for diseases related to the human microbiome | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen